Long noncoding RNA (lncRNA) <i>EIF3J-DT</i> induces chemoresistance of gastric cancer via autophagy activation

Luo, Yuhao; Zheng, Songbai; Wu, Qianying; Wu, Jianhua; Zhou, Rui; Wang, Chunling; Wu, Zhenzhen; Rong, Xiaoxiang; Huang, Na; Sun, Li; Bin, Jianping; Liao, Yulin; Shi, Min; Liao, Wangjun

doi:10.1080/15548627.2021.1901204

Cited by 147 publications

(83 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The experiment was repeated 3 times the genetic and phenotypic stability of their original tissues to a great extent and have a superior predictive ability of patient-specific responses to chemotherapy, highlighting a great promise for personalized therapy [19,20]. Different from previous studies that employed high-throughput RNA sequencing [21,22] (), the present study adopted mass spectrometry-based proteomics to explore the molecular mechanism of oxaliplatin resistance. Ubiquitin-mediated proteolysis, carbon metabolism, and VEGF signaling pathway were identified as novel characteristics of oxaliplatin-resistant organoids of CC patients.…”

Section: Discussionmentioning

confidence: 99%

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Sun

Luo

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background Resistance to oxaliplatin is a major obstacle for the management of locally advanced and metastatic colon cancer (CC). Although long noncoding RNAs (lncRNAs) play key roles in CC, the relationships between lncRNAs and resistance to oxaliplatin have been poorly understood yet. Methods Chemo-sensitive and chemo-resistant organoids were established from colon cancer tissues of the oxaliplatin-sensitive or -resistant patients. Analysis of the patient cohort indicated that lnc-RP11-536 K7.3 had a potential oncogenic role in CC. Further, a series of functional in vitro and in vivo experiments were conducted to assess the effects of lnc-RP11-536 K7.3 on CC proliferation, glycolysis, and angiogenesis. RNA pull-down assay, luciferase reporter and fluorescent in situ hybridization assays were used to confirm the interactions between lnc-RP11-536 K7.3, SOX2 and their downstream target HIF-1α. Results In this study, we identified a novel lncRNA, lnc-RP11-536 K7.3, was associated with resistance to oxaliplatin and predicted a poor survival. Knockout of lnc-RP11-536 K7.3 inhibited the proliferation, glycolysis, and angiogenesis, whereas enhanced chemosensitivity in chemo-resistant organoids and CC cells both in vitro and in vivo. Furthermore, we found that lnc-RP11-536 K7.3 recruited SOX2 to transcriptionally activate USP7 mRNA expression. The accumulative USP7 resulted in deubiquitylation and stabilization of HIF-1α, thereby facilitating resistance to oxaliplatin. Conclusion In conclusion, our findings indicated that lnc-RP11-536 K7.3 could promote proliferation, glycolysis, angiogenesis, and chemo-resistance in CC by SOX2/USP7/HIF-1α signaling axis. This revealed a new insight into how lncRNA could regulate chemosensitivity and provide a potential therapeutic target for reversing resistance to oxaliplatin in the management of CC.

show abstract

Section: Discussionmentioning

confidence: 99%

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Sun

Luo

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Although these RNAs do not directly translate into proteins ( Gupta et al, 2020 ), driving evidence clarifies that they play an essential role in biological functions ( Chen et al, 2020b ; Jantrapirom et al, 2021 ; Jin et al, 2021 ; Lai et al, 2021 ; Zhang et al, 2021b ). Such is the case of long non-coding RNAs (lncRNAs), which are no less than 200 nucleotides and participate in the initiation and progression of various diseases, especially cancers ( Chen et al, 2020a ; Huang et al, 2021 ; Kotani et al, 2021 ; Luo et al, 2021 ; Teng et al, 2021 ). Abnormal expression of these lncRNAs is involved in a variety of biological processes in tumors via regulation of gene expression that affects tumor size, metastasis, pathological stage, and prognosis in patients ( Yin et al, 2018 ; Shuai et al, 2020 ; Li et al, 2021a ; Zheng et al, 2021 ; Zhong et al, 2021b ).…”

Section: Introductionmentioning

confidence: 99%

Promising Advances in LINC01116 Related to Cancer

Xu¹,

Yu²,

Zhang³

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are RNAs with a length of no less than 200 nucleotides that are not translated into proteins. Accumulating evidence indicates that lncRNAs are pivotal regulators of biological processes in several diseases, particularly in several malignant tumors. Long intergenic non-protein coding RNA 1116 (LINC01116) is a lncRNA, whose aberrant expression is correlated with a variety of cancers, including lung cancer, gastric cancer, colorectal cancer, glioma, and osteosarcoma. LINC01116 plays a crucial role in facilitating cell proliferation, invasion, migration, and apoptosis. In addition, numerous studies have recently suggested that LINC01116 has emerged as a novel biomarker for prognosis and therapy in malignant tumors. Consequently, we summarize the clinical significance of LINC01116 associated with biological processes in various tumors and provide a hopeful orientation to guide clinical treatment of various cancers in future studies.

show abstract

“…In recent years, an increasing number of studies have shown that the dysregulation of lncRNAs, such as lncRNA MALAT1 and DRAIC, plays important roles in the initiation and development of PCa [17][18][19][20]. LncRNA EIF3J-AS1 was found to function as an oncogene in different kinds of cancer [8,10] and to induce chemoresistance [21]. However, the role of EIF3J-AS1 has not been described with regard to PCa.…”

Section: Discussionmentioning

confidence: 99%

LncRNA EIF3J-AS1 functions as an oncogene by regulating MAFG to promote prostate cancer progression

Wang¹,

Qin²,

Guo³

et al. 2022

J. Cancer

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) can modulate various biological processes and behaviors in most human cancers. LncRNA EIF3J-AS1 has been reported as an oncogene in various tumors, but whether it exerts functions in malignant progression and gene expression in prostate cancer (PCa) remains unknown. In this study, we investigated the high level of EIF3J-AS1 in PCa tissues and cells, and used functional assays to show that knocking down EIF3J-AS1 inhibited PCa cell proliferation and metastatic ability. A preliminary mechanistic investigation also showed that EIF3J-AS1 may increase the expression of MAF bZIP transcription Factor G (MAFG) in PCa. The expression correlation between EIF3J-AS1 and MAFG was found to be positive in PCa tissues. Finally, rescue assays showed that MAFG might be involved in the EIF3J-AS1-mediated malignant phenotype in PCa cells. This study demonstrated that EIF3J-AS1/MAFG may play a key role in facilitating PCa progression.

show abstract

Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation

Cited by 147 publications

References 68 publications

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Promising Advances in LINC01116 Related to Cancer

LncRNA EIF3J-AS1 functions as an oncogene by regulating MAFG to promote prostate cancer progression

Contact Info

Product

Resources

About